Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for HER2-mutant non-small-cell lung cancer, drawn from the whole corpus: 28 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No trial yet compares an oral HER2 inhibitor with an antibody-drug conjugate or settles the sequence.
Interstitial lung disease from trastuzumab deruxtecan is unpredictable and occasionally fatal.
HER2-amplified and HER2-overexpressing lung cancers without a mutation lack a defined standard.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
Confirmed response rate 71% in 75 previously treated patients naive to HER2-directed therapy; 48% after a HER2 antibody-drug conjugate; FDA accelerated approval August 2025.
ORR ~64%; accelerated approval Nov 2025.
A milestone in how this cancer is treated.
Confirmed response rate 49.
A milestone in how this cancer is treated.